Introduction {#s1}
============

CHA~2~DS~2~-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or thromboembolism, vascular disease, age 65--74 years and female sex) is the most widely used and validated clinical prediction score for assessment of ischaemic stroke (IS) risk in individuals with atrial fibrillation (AF). The score ranges from 0 to 9, and assigns 1 or 2 points for each stroke risk factor.[@R1] CHA~2~DS~2~-VASc aims to identify individuals with the lowest stroke risk (CHA~2~DS~2~-VASc=0) in whom prevention with anticoagulants is not advised. The advice for individuals with one stroke risk factor (CHA~2~DS~2~-VASc=1) varies in current clinical practice guidelines, as it remains uncertain whether the benefits of anticoagulants outweigh the harms.[@R2] [@R3] [@R4]

A recent systematic review of incidence rates (IRs) of IS in individuals with CHA~2~DS~2~-VASc=1 reported highly heterogeneous annualised rates ranging from 0.1% to 6.6% across studies, with wide uncertainty (0--3.23%) in the pooled estimate of 1.6%.[@R5] Among the 10 included studies, there were 0 studies that involved individuals across both primary and secondary care. Primary care accounts for over 40% of initial AF diagnoses.[@R6] Therefore without the inclusion of these individuals, it is unclear whether previously reported stroke rates are representative of the full patient pathway. Furthermore, in many countries (including the UK, Denmark and Sweden) clinical information coded and recorded electronically in secondary care is not integrated with that of primary care.[@R7] Thus, without the inclusion of risk factors diagnosed in primary care, previous studies based on secondary care data may have inaccurately calculated individuals\' CHA~2~DS~2~-VASc scores ([figure 1](#HEARTJNL2016309910F1){ref-type="fig"}).[@R8] Lastly, without conducting net clinical benefit (NCB) analyses, which weigh up benefits and harms of anticoagulants, the review was limited in the extent to which it could inform recommendations for clinical practice guidelines.

![Example of one patient\'s actual pathway and how information is captured in primary care and secondary care records. This illustrates how lack of integration of primary and secondary care information may lead to underestimation of CHA~2~DS~2~-VASc scores. Patient interactions occurring in primary and secondary care are colour-coded green and blue, respectively. +1 indicates scoring of one CHA~2~DS~2~-VASc risk factor point. As shown, this patient has CHA2DS2-VASc=1 based on secondary care records only, CHA2DS2-VASc=2 based on primary care records only, but is truly CHA2DS2-VASc=3 based on integrated primary and secondary care records. INR, International Normalised Ratio.](heartjnl-2016-309910f01){#HEARTJNL2016309910F1}

We therefore implemented the CHA~2~DS~2~-VASc score in a large, nationally representative linked electronic health record (EHR) study of 70 206 individuals with initial record of diagnosis of non--valvular AF in primary or secondary care in England in 1998--2010. We selected an observation period prior to the introduction of direct oral anticoagulants (DOACs), in order to more accurately study outcomes with warfarin. Our objectives were (1) to investigate incidence of IS in individuals with AF across stroke risk and across primary and secondary care, and (2) to consider benefits and harms of warfarin in NCB analyses.

Methods {#s2}
=======

Data sources {#s2a}
------------

We used available data from the population-based CALIBER (ClinicAl research using LInked Bespoke studies and EHRs) study.[@R7] CALIBER connects four national sources of EHRs in England, including a subset of primary care data from the Clinical Practice Research Datalink GP OnLine Database (CPRD GOLD),[@R9] secondary care data from Hospital Episode Statistics (HES),[@R10] data on admissions to hospital with an acute coronary syndrome from the Myocardial Ischaemic National Audit Project[@R11] and cause-specific mortality data from the Office of National Statistics (ONS).[@R12] The denominator population comprises individuals captured in CPRD GOLD, who are representative of the UK population in terms of gender, age, ethnicity[@R13] and overall mortality.[@R14] For this analysis we used CPRD GOLD, HES and ONS. CPRD GOLD is coded using Read clinical terms,[@R15] and HES and ONS using the International Classification of Diseases V.10 (ICD--10).[@R16] A key objective of CALIBER is to facilitate transparent and reproducible research of these data through the publication of disease phenotypes and tools to support statistical analysis, and these can be found freely available at caliberresearch.org. CALIBER research has been shown to replicate known and discover new associations with risk factors for the onset of disease.[@R17]

Selection of individuals with non-valvular AF {#s2b}
---------------------------------------------

We used the previously reported CALIBER phenotype algorithm for AF to identify all individuals with a diagnosis in primary or secondary care between 1998 and 2010.[@R6] The algorithm includes primary and secondary care (main and subsidiary) recorded diagnoses, and inferred diagnoses based on warfarin prescriptions without prior thromboembolic disease. In order to define non-valvular AF we then excluded individuals with a record of mitral valve disease, rheumatic mitral regurgitation, and prosthetic mitral, aortic or unspecified valve replacements,[@R21] based on 45 Read codes, 9 ICD--10 codes and 11 operation and procedure codes (see online [supplementary table](#SM1){ref-type="supplementary-material"} S1 for the code list).
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CHA~2~DS~2~-VASc {#s2c}
----------------

We generated baseline CHA~2~DS~2~-VASc scores for each individual by assigning 1 or 2 points for each stroke risk factor. Risk factors were defined according to existing CALIBER phenotypes (available at caliberresearch.org), which use all available clinical information across the linked primary and secondary care records. In brief, age and sex were obtained from general practice registration information; congestive heart failure, diabetes mellitus (types I, II and unclassified), history of stroke or thromboembolism (stroke, transient ischaemic attack or systemic embolism), and vascular disease (myocardial infarction (MI) or peripheral artery disease (PAD)) from clinical diagnosis codes; and hypertension from diagnosis codes, two or more values of systolic or diastolic blood pressure measurements above UK diagnostic thresholds of 140/90 mm Hg,[@R22] or through repeat prescriptions for blood pressure lowering medications.

Warfarin {#s2d}
--------

We considered warfarin use throughout the entire study period and extracted information on prescriptions and international normalised ratio (INR) tests from primary care records. Prescriptions data include drug type and date of administration but do not have information on pharmacy collections. Individuals were considered to be using warfarin continuously during follow-up if a prescription or INR test was administered every 30 days. This allowed each individual\'s follow-up time to be divided into periods with and without use of warfarin.[@R23]

Follow-up and end points {#s2e}
------------------------

Individuals entered the study at their earliest coded diagnosis of AF during January 1998 and March 2010, provided they were aged 18 years and over and with a minimum of 1 year of continuous registration at a general practice with acceptable data recording standards. We followed individuals for clinical diagnoses of IS and unclassified strokes, and for haemorrhagic strokes (HSs) (intracerebral and subarachnoid haemorrhage) as recorded in primary or secondary care and mortality registry records. ISs and unclassified strokes were combined, as it has previously been shown that 87% of all strokes are ischaemic.[@R24] A clearance period of 2 weeks was imposed from date of recorded AF diagnosis, such that any stroke occurring during this time was attributed to baseline risk and not counted as an end point. The rationale is that AF is commonly first detected when an individual presents with a complication, such as stroke.[@R25] Clearance periods are also imperative when analysing linked EHRs to avoid double counting, as the same event can be recorded more than once, and in multiple data sources.[@R26] Total follow-up time for each individual was calculated as the number of days from the end of the clearance period to the point of censoring. Individuals were censored in the event of an IS or HS end point, death (from a cause other than a stroke end point), transfer out of general practice, or last date of data collection.

Data analysis {#s2f}
-------------

We compared baseline CHA~2~DS~2~-VASc risk factors in individuals with initial record of diagnosis in primary and secondary care using the Student\'s t-test or χ^2^ test, and these are presented as proportions, means (SD) and medians (range, IQR), as appropriate. We assessed the completeness of recording CHA~2~DS~2~-VASc risk factors in each data source using absolute proportions, that is, number (%) of total cases captured in primary care records, and in secondary care records, compared with both data sources linked. We calculated IRs and 95% CIs per 100 person-years (PYs) (IR (95% CI)/100 PY) for IS and HS by dividing the number of end points by the accrued number of PYs. We assessed whether IRs were robust by comparing with estimates adjusted for propensity score quintiles. This accounts for whether individuals were more likely or less likely to receive treatment with warfarin. We conducted NCB analyses comparing number of ISs avoided, against number of HSs experienced per 100 PYs of warfarin use (NCB (95% CI)/100 PY). We used the formula: (IS rate~without\ warfarin~−IS rate~with\ warfarin~)−1.5 (HS rate~with\ warfarin~−HS rate~without\ warfarin~), whereby a positive estimate indicates a treatment benefit, and a negative estimate indicates treatment harm.[@R27] We regarded the NCB as significant if the 95% CI did not span both the positive and negative scales. All analyses were conducted in Stata/SE V.13 and figures were generated in R (V.3.2.0).

Results {#s3}
=======

Population characteristics {#s3a}
--------------------------

### Population overall {#s3a1}

The overall study population comprised 70 206 individuals with non-valvular AF with median age of 77.9 years (range: 18.0--108.7, IQR: 15.1), and median follow-up of 2.20 years (range: 0.03--12.2, IQR: 4.2). Of the individuals 34 286 (48.8%) were women, and 2486 (3.5%) had CHA~2~DS~2~-VASc=0, 5637 (8.0%) had CHA~2~DS~2~-VASc=1 and 9339 (13.3%) had CHA~2~DS~2~-VASc=2. The mean (SD) CHA~2~DS~2~-VASc score of the overall population was 3.7 (1.8).

### Individuals with initial record of diagnosis in primary versus secondary care {#s3a2}

Of the individuals 29 568 (42.1%) had initial record of diagnosis of AF in primary care, and 40 638 (57.9%) had initial record of diagnosis in secondary care. Individuals with initial record of diagnosis in secondary care were older (median (IQR) age: 79.1 (15.0) years vs 76.5 (14.8) years), more likely to be female (50.1% vs 47.1%) and were less likely to have CHA~2~DS~2~-VASc=0 (2.9% vs 4.4%), CHA~2~DS~2~-VASc=1 (6.6% vs 10.1%) or CHA~2~DS~2~-VASc=2 (11.1% vs 6.6%) than those with initial record of diagnosis in primary care. The mean (SD) CHA~2~DS~2~-VASc score among individuals with initial record of diagnosis of AF in primary care compared with secondary care was 3.3 (1.7) vs 4.0 (1.8). As [table 1](#HEARTJNL2016309910TB1){ref-type="table"} shows, individuals with initial record of diagnosis in secondary care had a higher proportion of all CHA~2~DS~2~-VASc risk factors.

###### 

Comparison of baseline CHA~2~DS~2~-VASc risk factors in individuals with initial record of diagnosis in primary or secondary care

                                                                  Initial record of diagnosis                                   
  --------------------------------------------------------------- ----------------------------- ------ -------- ------ -------- ------
  **C**ongestive heart failure                                    4768                          16.1   12 664   31.2   17 432   24.8
  **H**ypertension                                                23 946                        81.0   33 817   83.2   57 763   82.3
   Diagnosis                                                      16 616                        56.2   25 273   62.2   41 889   59.7
   Blood pressure medication                                      20 979                        71.0   30 164   74.2   51 143   72.9
   Blood pressure measures                                        17 281                        58.4   22 329   55.0   39 610   56.4
  **A**ge ≥ 75 years[@R2]                                         16 318                        55.2   25 872   63.7   42 190   60.1
  **D**iabetes                                                    3316                          11.2   6673     16.4   9989     14.2
  **S**troke/transient ischaemic attack/ systemic embolism[@R2]   3887                          13.2   8938     22.0   12 825   18.3
  **V**ascular disease                                            4049                          13.7   9783     24.1   13 832   19.7
   Myocardial infarction                                          2635                          8.9    6950     17.1   9585     13.7
   Peripheral vascular disease                                    1776                          6.0    3927     9.7    5703     8.1
  **A**ge 65--74 years                                            7744                          26.2   8552     21.0   16 296   23.2
  **S**ex **c**ategory (female)                                   13 930                        47.1   20 356   50.1   34 286   48.8
  CHA~2~DS~2~-VASc scores                                                                                                       
   0                                                              1305                          4.4    1181     2.9    2486     3.5
   1                                                              2972                          10.1   2665     6.6    5637     8.0
   2                                                              4820                          16.3   4519     11.1   9339     13.3
   3                                                              6663                          22.5   7107     17.5   13 770   19.6
   4                                                              7332                          24.8   9578     23.6   16 910   24.1
   5                                                              3712                          12.6   7514     18.5   11 226   16.0
   6                                                              1866                          6.3    4906     12.1   6772     9.7
   7                                                              724                           2.5    2341     5.8    3065     4.4
   8                                                              156                           0.5    707      1.7    863      1.2
   9                                                              18                            0.1    120      0.3    138      0.2

### Individuals with versus without use of warfarin {#s3a3}

Of the individuals 30 067 (42.8%) underwent at least one period of warfarin use during follow-up; 50.1% of these had initial record of diagnosis in primary care (n=15 077) and 49.9% had initial record of diagnosis in secondary care (n=14 990). Individuals without use of warfarin were older (median (IQR) age: 80.7 (15.2) years vs 74.9 (13.4) years) and had a higher proportion of heart failure, but there was no difference in diagnosed hypertension, vascular disease (MI or PAD), diabetes and previous strokes, when compared with those with at least one period of warfarin use (see online [supplementary table S2](#SM1){ref-type="supplementary-material"}).

### Men versus women {#s3a4}

Women were older (median (IQR) age: 80.8 (13.3) years vs 74.9 (15.9) years) and had a higher proportion of heart failure, hypertension and previous strokes, while vascular disease (MI and PAD) and diabetes were more common in men (see online [supplementary table](#SM1){ref-type="supplementary-material"} S3).

Completeness of risk factors and reclassification of CHA~2~DS~2~-VASc scores {#s3b}
----------------------------------------------------------------------------

The completeness of recording CHA~2~DS~2~-VASc risk factors in primary and secondary care records ranged from 40.4% to 73.7% complete in secondary care records, and from 69.1% to 99.0% in primary care records (see online [supplementary table](#SM1){ref-type="supplementary-material"} S4 and figure S1). Among individuals with initial record of diagnosis in secondary care, 975 (45.2%) were reclassified from CHA~2~DS~2~-VASc=0 to CHA~2~DS~2~-VASc≥1 and 2172 (53.7%) from CHA~2~DS~2~-VASc=1 to CHA~2~DS~2~-VASc≥2 when scores were calculated using linked primary--secondary care records. Only 15 (1.1%) individuals with initial record of diagnosis in primary care were reclassified from CHA~2~DS~2~-VASc=0 to CHA~2~DS~2~-VASc≥1 and 81 (2.7%) from CHA~2~DS~2~-VASc=1 to CHA~2~DS~2~-VASc≥2. For CHA~2~DS~2~-VASc scores calculated based on primary and secondary care records compared with both data sources linked, see online [supplementary table S5](#SM1){ref-type="supplementary-material"}.

Stroke incidence {#s3c}
----------------

### IS incidence in individuals with initial record of diagnosis in primary or secondary care {#s3c1}

Seven thousand and five ISs occurred over 216 446 PYs, with IR (95% CI)/100 PY of 3.2 (3.2 to 3.3). Compared with individuals with initial record of diagnosis in secondary care, those in primary care had lower overall IS incidence (IR (95% CI)/100 PY: 2.3 (2.2 to 2.4) vs 4.3 (4.2 to 4.4), p value=0.00), however as [figure 2](#HEARTJNL2016309910F2){ref-type="fig"} shows there were no differences in incidence at CHA~2~DS~2~-VASc=0 (IR (95% CI)/100 PY: 0.2 (0.1 to 0.3) vs 0.3 (0.2 to 0.5), p value=0.16), CHA~2~DS~2~-VASc=1 (IR (95% CI)/100 PY: 0.6 (0.4 to 0.7) vs 0.7 (0.6 to 0.9), p value=0.08) or CHA~2~DS~2~-VASc=2 (IR (95% CI)/100 PY: 1.1 (1.00 to 1.3) vs 1.4 (1.2 to 1.6), p value=0.05). IRs in individuals with initial record of diagnosis in primary or in secondary care across all CHA~2~DS~2~-VASc scores are provided in [table 2](#HEARTJNL2016309910TB2){ref-type="table"}.

###### 

Incidence rates (95% CIs) per 100 person-years of ischaemic stroke by CHA~2~DS~2~-VASC scores in individuals with initial record of diagnosis in primary or secondary care

                            Initial record of diagnosis                                                                                       
  ------------------------- ----------------------------- -------------------------- ---------- --------------------------- ------ ---------- --------------------------
  CHA~2~DS~2~-VASc scores                                                                                                                     
   0                        12                            0.2 (0.1 to 0.3)           16         0.3 (0.2 to 0.5)            0.16   28         0.2 (0.2 to 0.4)
   1                        77                            0.6 (0.4 to 0.7)           76         0.7 (0.6 to 0.9)            0.08   153        0.6 (0.5 to 0.7)
   2                        244                           1.1 (1.0 to 1.3)           209        1.4 (1.2 to 1.6)            0.05   453        1.2 (1.1 to 1.3)
   3                        528                           2.0 (1.8 to 2.2)           485        2.4 (2.2 to 2.6)            0.01   1013       2.2 (2.0 to 2.3)
   4                        766                           2.9 (2.7 to 3.2)           907        3.9 (3.7 to 4.2)            0.00   1673       3.4 (3.2 to 3.6)
   5                        450                           3.9 (3.5 to 4.2)           966        6.5 (6.1 to 6.9)            0.00   1416       5.3 (5.1 to 5.6)
   6                        332                           6.4 (5.7 to 7.1)           1028       12.0 (11.3 to 12.8)         0.00   1360       9.9 (9.4 to 10.4)
   7                        146                           7.7 (6.6 to 9.1)           546        14.8 (13.6 to 16.1)         0.00   692        12.4 (11.5 to 13.3)
   8                        34                            9.3 (6.6 to 12.9)          151        15.8 (13.5 to 18.5)         0.00   185        13.9 (12.1 to 16.1)
   9                        5                             13.4 (5.6 to 32.3)         27         22.1 (15.2 to 32.3)         0.31   32         20.0 (14.2 to 28.4)
   **0--9**                 **2594**                      **2.3 (2.2** to **2.4)**   **4411**   **4.3 (4.2** to **4.42)**   0.00   **7005**   **3.2 (3.2** to **3.3)**

Bold text is used to differentiate the rates among individual scores 0,1, 2, ..., 9, from all scores 0 to 9 combined.

![Incidence rates (95% CIs) per 100 person-years of ischaemic stroke by CHA~2~DS~2~-VASC scores in individuals with initial record of diagnosis in primary or secondary care.](heartjnl-2016-309910f02){#HEARTJNL2016309910F2}

### IS incidence by warfarin use {#s3c2}

One thousand and fifteen (14.5%) ISs occurred over 59 006 PYs of warfarin use and 5990 (85.5%) over 157 439 PYs of no warfarin use. IRs were lower with warfarin use (IR (95% CI)/100 PY: 1.7 (1.6 to 1.8) vs 3.8 (3.7 to 3.9), p value=0.00), with an IR ratio (95% CI) of 0.5 (0.4 to 0.5). For CHA~2~DS~2~-VASc=0, CHA~2~DS~2~-VASc=1 and CHA~2~DS~2~-VASc=2, IRs with versus without use of warfarin were (IR (95% CI)/100 PY: 0.4 (0.2 to 0.8) vs 0.2 (0.1 to 0.3), p value=0.16), (IR (95% CI)/100 PY: 0.4 (0.3 to 0.7) vs 0.7 (0.6 to 0.8), p value=0.03) and (IR (95% CI)/100 PY: 0.8 (0.7 to 1.0) vs 1.4 (1.3 to 1.6), p value=0.00). As [figures 3](#HEARTJNL2016309910F3){ref-type="fig"} and [4](#HEARTJNL2016309910F4){ref-type="fig"} show IRs were lower with use of warfarin from CHA~2~DS~2~-VASc≥2 in men (IR (95% CI)/100 PY: 0.9 (0.7 to 1.1) vs 1.7 (1.5 to 1.9), p value=0.00), and from CHA~2~DS~2~-VASc≥3 in women (IR (95% CI)/100 PY: 0.7 (0.5 to 1.0) vs 2.3 (2.0 to 2.5), p value=0.00). IRs by sex and use of warfarin across all CHA~2~DS~2~-VASc scores are provided in [table 3](#HEARTJNL2016309910TB3){ref-type="table"}. IRs adjusted for propensity score quintiles were consistent with the unadjusted estimates (see online [supplementary table](#SM1){ref-type="supplementary-material"} S6).

![Incidence rates (95% CIs) per 100 person-years of ischaemic stroke in men by CHA~2~DS~2~-VASC scores, and use of warfarin. Individuals could contribute follow-up time to periods with and without warfarin.](heartjnl-2016-309910f03){#HEARTJNL2016309910F3}

![Incidence rates (95% CIs) per 100 person-years of ischaemic stroke in women by CHA~2~DS~2~-VASC scores, and use of warfarin. Individuals could contribute follow-up time to periods with and without warfarin.](heartjnl-2016-309910f04){#HEARTJNL2016309910F4}

###### 

Incidence rates (95% CIs) per 100 person-years of ischaemic stroke by CHA~2~DS~2~-VASC scores, sex and use of warfarin

                               With warfarin   Without warfarin                      Population overall                                
  ---------------------------- --------------- -------------------------- ---------- -------------------------- ----------- ---------- --------------------------
  * CHA~2~DS~2~-VASc scores*                                                                                                           
   Overall population                                                                                                                  
   0                           7               0.4 (0.2 to 0.8)           21         0.2 (0.1 to 0.3)           0.23        28         0.2 (0.2 to 0.4)
   1                           27              0.4 (0.3 to 0.7)           126        0.7 (0.6 to 0.8)           0.03        153        0.6 (0.5 to 0.7)
   2                           87              0.8 (0.7 to 1.0)           366        1.4 (1.3 to 1.6)           0.00        453        1.2 (1.1 to 1.3)
   3                           144             1.0 (0.9 to 1.2)           869        2.6 (2.5 to 2.8)           0.00        1013       2.2 (2.0 to 2.3)
   4                           226             1.7 (1.5 to 2.0)           1447       4.0 (3.8 to 4.2)           0.00        1673       3.4 (3.2 to 3.6)
   5                           233             3.2 (2.8 to 3.6)           1183       6.2 (5.8 to 6.5)           0.00        1416       5.3 (5.1 to 5.6)
   6                           159             4.2 (3.6 to 4.8)           1201       12.1 (11.4 to 12.8)        0.00        1360       9.9 (9.4 to 10.4)
   7                           111             7.1 (5.9 to 8.6)           581        14.5 (13.4 to 15.7)        0.00        692        12.4 (11.5 to 13.4)
   8                           18              4.8 (3.0 to 7.6)           167        17.6 (15.1 to 20.5)        0.00        185        14.0 (12.1 to 16.2)
   9                           3               7.5 (2.4 to 23.3)          29         24.3 (16.9 to 35.0)        0.03        32         20.1 (14.2 to 28.4)
   **0--9**                    **1015**        **1.7 (1.6** to **1.8)**   **5990**   **3.8 (3.7** to **3.9)**   **0. 00**   **7005**   **3.2 (3.2** to **3.3)**
  **Men**                                                                                                                              
   0                           7               0.4 (0.2 to 0.8)           21         0.2 (0.1 to 0.3)           0.23        28         0.2 (0.2 to 0.4)
   1                           25              0.5 (0.3 to 0.7)           112        0.8 (0.6 to 0.9)           0.01        137        0.7 (0.6 to 0.8)
   2                           75              0.9 (0.7 to 1.1)           306        1.7 (1.5 to 1.9)           0.00        381        1.5 (1.3 to 1.6)
   3                           106             1.3 (1.1 to 1.5)           550        2.9 (2.7 to 3.2)           0.00        656        2.4 (2.2 to 2.6)
   4                           119             2.2 (1.8 to 2.6)           489        4.3 (3.9 to 4.7)           0.00        608        3.6 (3.3 to 3.9)
   5                           122             4.1 (3.4 to 4.9)           491        7.8 (7.1 to 8.5)           0.00        613        6.6 (6.1 to 7.1)
   6                           51              4.1 (3.1 to 5.4)           312        11.5 (10.3 to 12.9)        0.00        363        9.2 (8.3 to 10.1)
   7                           27              6.1 (4.3 to 9.2)           129        14.5 (12.2 to 17.3)        0.00        156        11.9 (10.1 to 13.9)
   8                           1               1.9 (0.3 to 13.3)          20         14.5 (9.4 to 22.5)         0.01        21         11.0 (7.2 to 16.8)
   **0--8**                    **533**         **1.6 (1.4** to **1.7)**   **2430**   **2.9 (2.8** to **3.1)**   **0.00**    **2963**   **2.5 (2.4** to **2.6)**
  **Women**                                                                                                                            
   1                           2               0.4 (0.1 to 1.5)           14         0.4 (0.2 to 0.7)           0.97        16         0.4 (0.3 to 0.7)
   2                           12              0.5 (0.3 to 0.9)           60         0.7 (0.6 to 0.9)           0.24        72         0.7 (0.5 to 0.8)
   3                           38              0.7 (0.5 to 1.0)           319        2.3 (2.0 to 2.5)           0.00        357        1.8 (1.6 to 2.0)
   4                           107             1.4 (1.1 to 1.7)           958        3.9 (3.7 to 4.1)           0.00        1065       3.3 (3.1 to 3.5)
   5                           111             2.5 (2.1 to 3.0)           692        5.4 (5.0 to 5.8)           0.00        803        4.7 (4.4 to 5.0)
   6                           108             4.2 (3.5 to 5.0)           889        12.3 (11.5 to 13.1)        0.00        997        10.2 (9.5 to 10.8)
   7                           84              7.4 (6.0 to 9.2)           452        14.5 (13.2 to 15.9)        0.00        536        12.6 (11.6 to 13.7)
   8                           17              5.3 (3.3 to 8.5)           147        18.1 (15.4 to 21.3)        0.00        164        14.5 (12.4 to 16.9)
   9                           3               7.5 (2.4 to 23.3)          29         24.3 (16.9 to 35.0)        0.03        32         20.1 (14.2 to 28.4)
   **1--9**                    **482**         **2.0 (1.8** to **2.1)**   **3560**   **4.8 (4.6** to **4.9)**   **0.00**    **4042**   **4.1 (3.9** to **4.2)**

### NCB of warfarin {#s3c3}

Nine hundred and six HSs occurred over 224 777 PYs. The overall NCB of warfarin was 1.9 (1.8 to 2.1) ISs avoided per 100 PYs. For CHA~2~DS~2~-VASc=0, CHA~2~DS~2~-VASc=1 and CHA~2~DS~2~-VASc=2, NCB was (NCB (95% CI)/100 PY: −0.3 (−0.8 to 0.1)), (NCB (95% CI)/100 PY: 0.1 (−0.2 to 0.4)) and (NCB (95% CI)/100 PY: 0.2 (−0.1 to 0.6)), respectively. A significant positive NCB was observed from CHA~2~DS~2~-VASc≥2 in men (NCB (95% CI)/100 PY: 0.5 (0.1 to 0.9)) and from CHA~2~DS~2~-VASc≥3 in women (NCB (95% CI)/100 PY: 1.5 (1.1 to 1.9)). NCB estimates across all CHA~2~DS~2~-VASc scores are provided in [table 4](#HEARTJNL2016309910TB4){ref-type="table"}.

###### 

Net clinical benefit (95% CIs) per 100 person-years with warfarin, by CHA~2~DS~2~-VASC scores and sex

                              Total stroke events   Net clinical benefit   
  --------------------------- --------------------- ---------------------- --------------------
  *CHA~2~DS~2~-VASc scores*                                                
  Overall population                                                       
   0                          28                    8                      −0.3 (−0.8 to 0.1)
   1                          153                   54                     0.1 (−0.2 to 0.4)
   2                          453                   95                     0.2 (−0.1 to 0.6)
   3                          1013                  165                    1.5 (1.2 to 1.8)
   4                          1673                  237                    2.2 (1.8 to 2.6)
   5                          1416                  180                    3.2 (2.6 to 3.8)
   6                          1360                  104                    7.7 (6.7 to 8.8)
   7                          692                   45                     7.2 (5.2 to 9.1)
   8                          185                   18                     12.8 (8.9 to 16.9)
   9                          32                    0                      16.8 (1.8 to 31.5)
   **0--9**                   7005                  906                    1.9 (1.8 to 2.1)
  Men                                                                      
   0                          28                    8                      −0.3 (−0.8 to 0.1)
   1                          137                   48                     0.1 (−0.2 to 0.4)
   2                          381                   79                     0.5 (0.1 to 0.9)
   3                          656                   103                    1.5 (1.1 to 1.9)
   4                          608                   93                     2.0 (1.3 to 2.7)
   5                          613                   88                     3.9 (2.6 to 4.9)
   6                          363                   26                     7.1 (5.2 to 9.1)
   7                          156                   15                     8.6 (4.7 to 13.0)
   8                          21                    3                      15.9 (7.0 to 25.7)
   **0--8**                   2963                  463                    1.2 (1.0 to 1.4)
  Women                                                                    
   1                          16                    6                      0.3 (−0.4 to 0.8)
   2                          72                    16                     −0.1 (−0.6 to 0.3)
   3                          357                   62                     1.5 (1.1 to 1.9)
   4                          1065                  144                    2.4 (2.0 to 2.8)
   5                          803                   92                     3.1 (2.3 to 3.8)
   6                          997                   78                     8.0 (6.6 to 9.3)
   7                          536                   30                     6.8 (4.4 to 9.1)
   8                          164                   15                     12.4 (7.9 to 17.3)
   9                          32                    0                      16.8 (3.1 to 30.5)
   **1--9**                   4042                  443                    2.7 (2.4 to 3.0)

Discussion {#s4}
==========

We conducted the first large-scale nationally representative study of the potential benefits and harms of warfarin in individuals with AF across stroke risk and across primary and secondary care, and had two major findings. First, we confirmed that CHA~2~DS~2~-VASc accurately stratifies stroke risk in individuals with initial record of diagnosis in primary and secondary care, however clinical information recorded in both primary and secondary care must be considered in order to correctly assign CHA~2~DS~2~-VASc scores. Second, in individuals who were truly CHA~2~DS~2~-VASc=1, the absolute risk of IS (0.4 (0.3 to 0.7) with warfarin, and 0.7 (0.6 to 0.8) without warfarin) was relatively low and similar to the original derivation cohort of the CHA~2~DS~2~-VASc score,[@R1] and the NCB of warfarin was positive but non-significant (0.1 (−0.2 to 0.4)). We therefore found insufficient evidence to support anticoagulation with warfarin in individuals with CHA~2~DS~2~-VASc=1.

Findings in context {#s4a}
-------------------

Our IS IR of 0.7 (0.6 to 0.8) for CHA~2~DS~2~-VASc=1 without warfarin is low compared with previous reports (see online [supplementary table](#SM1){ref-type="supplementary-material"} S7) although consistent with the levels of uncertainty in a recent systematic review which reported an annual rate of 1.6% but with wide CIs (0% to 3.23%). Three lines of evidence from sensitivity analyses in men with CHA~2~DS~2~-VASc=1 (see online [supplementary table S8](#SM1){ref-type="supplementary-material"}) suggest that our estimates of stroke incidence are likely to be robust and offer reasons why they may differ from previous reports. First, as found in our main analysis, secondary care records underestimate stroke risk in half of individuals, and therefore previous studies which have predominantly focused on secondary care populations are likely to be biased by misclassification of CHA~2~DS~2~-VASc scores. In a sensitivity analysis of men with CHA~2~DS~2~-VASc=1 according to secondary care records (which included 53% who were truly CHA~2~DS~2~-VASc≥2), we found an IR of 1.4 (1.2 to 1.5), which is twice as high as the rate found for men who were truly CHA~2~DS~2~-VASc=1 (0.7 (0.6 to 0.8)) and similar to the meta-analysed rate found in the recent systematic review (1.6 (0 to 3.23)). Importantly, we confirm that if CHA~2~DS~2~-VASc risk is underestimated then stroke rates at the lower end of the CHA~2~DS~2~-VASc scale are overestimated, which has implications on treatment decisions. Second, Friberg, *et al*[@R25] reported that variation in the literature also exists because of differences in the way stroke is defined, and that a 44% higher IR is observed when including wider thromboembolic end points. We also confirmed this in a sensitivity analysis, and found that for men with CHA~2~DS~2~-VASc=1, the IR doubled from 0.7 (0.6 to 0.8) to 1.4 (1.2 to 1.5) when systemic embolism, pulmonary embolism and transient ischaemic attacks were included as a composite end point. Third, differences in previously reported stroke rates at CHA~2~DS~2~-VASc=1 may exist because not all 1-point scoring risk factors (heart failure, hypertension, diabetes mellitus, vascular disease, age 65--74 years, female sex) confer the same stroke risk.[@R28] In sensitivity analyses, we found that age 65--74 years conferred the highest stroke risk with IR of 1.2 (0.9 to 1.5). Thus, population-based IRs of CHA~2~DS~2~-VASc=1 will depend upon the distribution of 1-point scoring risk factors within the population.

Unlike the recent systematic review, our findings with regard to CHA~2~DS~2~-VASc=1 are supported by NCB analyses. To our knowledge, this is the first NCB analysis of warfarin to date that includes both individuals with initial record of diagnosis in primary and secondary care. We found a positive but non-significant treatment benefit of warfarin in individuals with CHA~2~DS~2~-VASc=1 (0.1 (−0.2 to 0.4)), and therefore insufficient evidence to support anticoagulation with warfarin in these individuals. Existing NCB analyses of warfarin have predominantly focused on individuals with initial record of diagnosis in secondary care, but have also shown an unclear benefit of treatment at CHA~2~DS~2~-VASc=1, including in both the nationwide Danish (−0.02 (−0.15 to 0.11)),[@R29] and Swedish (0.00 (not reported))[@R30] cohorts.

Direct oral anticoagulants {#s4b}
--------------------------

A question that remains is whether the newer DOACs (dabigatran, rivaroxaban, apixaban and edoxaban) have a role in the treatment of lower-risk individuals. In DOAC trials (eg, randomized evaluation of long-term anticoagulant therapy (RE-LY),[@R31] rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET-AF),[@R32] apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE)[@R33] and effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial Infarction 48 (ENGAGE AF-TIMI 48)[@R34]) all four agents were shown to be as effective in preventing ISs as warfarin, and associated with fewer HSs (see online [supplementary table](#SM1){ref-type="supplementary-material"} S9). We applied the trial reported relative risks of IS and HS to our data to consider the NCB of DOACs compared with no treatment. We found a significant positive NCB at CHA~2~DS~2~-VASc=1 across all agents (see online [supplementary table](#SM1){ref-type="supplementary-material"} S10), and therefore some, although extrapolated evidence that DOACs may be a more suitable treatment option for those at lower stroke risk. We caution against interpreting this finding too strongly, however, as the extrapolated model takes on multiple assumptions. First, it assumes that the relative risk reduction is constant over the entire period of follow-up, and across all levels of the CHA~2~DS~2~-VASc score. Second, it assumes that the trial population is representative of the general AF population. And third, it assumes that the benefit and harm end point definitions are equivalent. All four DOAC trials were approximately 2 years in duration, which is comparable to the 2.2 median years of follow-up in this analysis. However based on trial eligibility criteria, patients at CHA~2~DS~2~-VASc=1 were largely excluded from DOAC trials, and as previously demonstrated these trials represented only a half to two-thirds of the AF population in the UK.[@R35] Lastly, benefit and harm end point definitions did vary across trials (see online [supplementary table](#SM1){ref-type="supplementary-material"} S9).

Clinical implications {#s4c}
---------------------

We confirmed that CHA~2~DS~2~-VASc is valid for estimating stroke risk in individuals with initial record of diagnosis in primary and secondary care, and therefore advocate use of the score across the full patient pathway. While we showed that lack of integration of primary and secondary care information may lead to inaccurate CHA~2~DS~2~-VASc scores, we do not regard this as an issue at point of care as clinicians are able to verify stroke risk factors with patients directly. However with the advent of clinical decision support systems,[@R36] greater integration of primary and secondary care, and better recording of risk factors is urgently required in order to avoid undue patient harm through underestimation of stroke risk. Finally, we found insufficient evidence to support stroke prevention with warfarin at CHA~2~DS~2~-VASc=1, and this may have relevance for future treatment guidelines.[@R37]

Research implications {#s4d}
---------------------

Our findings highlight the value of linked EHRs in investigating individuals across the full pathway of primary and secondary care, and crucially in identifying individuals with CHA~2~DS~2~-VASc=1 in whom treatment guidelines have so far been unclear. Primary care records were instrumental in identifying individuals with CHA~2~DS~2~-VASc=1 and we therefore propose wider utilisation of existing and discovery of new primary care data sources for studying these individuals in future research, and in particular in 'real-world' comparative effectiveness studies of DOACs. By comparison, several large-scale secondary care data sources have already been used in AF research,[@R25] [@R28] [@R38] however these are currently limited in terms of depth of clinical information, such as lack of prescriptions or biomarker data. We therefore propose wider linkage of routinely collected records to other clinical data sources such as disease-specific registries where deeper phenotype information is contained.

Strengths and limitations {#s4e}
-------------------------

Our study\'s principal strength was the inclusion of individuals, risk factors and end points captured across the full pathway of primary and secondary care, which is unlike previous studies that have predominantly focused on secondary care populations. We were limited by the depth and completeness of clinical information currently recorded in primary and secondary care records, however, we minimised the impact of this by analysing multiple data sources, and adopting robust phenotypes for capturing individuals, risk factors and end points. An example of the value of CALIBER phenotypes comes from hypertension. As shown, the proportion of individuals with baseline hypertension rose significantly when information from diagnosis codes was supplemented with blood pressure measurements and prescriptions data. It is however still possible that some individuals, risk factors and end points may have been overlooked, but we consider the number affected to be minimal, and less than previous studies. While the lack of DOAC data may be considered a limitation of the present analysis, it should be noted that warfarin remains the most widely used oral anticoagulant. Therefore, studies involving pre-DOAC era cohorts such as this are still shown to be of contemporary relevance. Lastly, though we included a large sample size of 70 000 individuals, we found that only a quarter of the overall population had CHA~2~DS~2~-VASc scores 0, 1 and 2. We therefore cannot rule out the possibility that a positive NCB of warfarin may be observed at CHA~2~DS~2~-VASc=1 given a larger study population.

Conclusion {#s5}
==========

CHA~2~DS~2~-VASc accurately stratifies IS risk in individuals with AF across both primary and secondary care. However IRs of IS at CHA~2~DS~2~-VASc=1 are lower than previously reported, which may change the decision to start anticoagulation with warfarin in these individuals.

###### Key messages

What is already known on this subject?
--------------------------------------

-   It is unclear whether individuals with atrial fibrillation (AF) and CHA~2~DS~2~-VASc=1 benefit from stroke prevention with warfarin. Previous large-scale, population-based studies have reported incidence of ischaemic stroke (IS) in individuals with CHA~2~DS~2~-VASc=1; however have neglected the full patient pathway by focusing on those with initial record of diagnosis in secondary care.

What might this study add?
--------------------------

-   We confirmed that CHA~2~DS~2~-VASc accurately stratifies IS risk in individuals with AF across both primary and secondary care, however incidence rates (IRs) at CHA~2~DS~2~-VASc=1 are lower than previously reported. We found a significant positive net clinical benefit of warfarin from CHA~2~DS~2~-VASc≥2 in men and from CHA~2~DS~2~-VASc≥3 in women, with 0.5 (0.1 to 0.9) and 1.5 (1.1 to 1.9) ISs avoided per 100 person-years of warfarin treatment, respectively.

How might this impact on clinical practice?
-------------------------------------------

-   IRs at CHA~2~DS~2~-VASc=1 are lower than previously reported, which may change the decision to start anticoagulation with warfarin in these individuals.
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